Shared on22 Oct 25
Analysts have modestly adjusted their price target for Xvivo Perfusion, maintaining the fair value estimate at SEK 322.6 per share. This reflects minor updates in projected growth and profitability metrics.
Shared on08 Oct 25Fair value Decreased 6.66%
Narrative Update on Xvivo Perfusion Analysts have lowered their fair value estimate for Xvivo Perfusion to SEK 322.6 from SEK 345.6. The updated price target reflects revised assumptions on profit margins and revenue growth, as well as increased confidence signaled by a recent upgrade to Buy. Analyst Commentary Analysts have provided updated perspectives following the recent price target adjustment and rating upgrade for Xvivo Perfusion.
Shared on24 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25Fair value Decreased 2.21%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 2.25%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25Fair value Decreased 8.19%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25Fair value Increased 38%
AnalystConsensusTarget has increased future PE multiple from 31.7x to 35.3x.